Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAYLA M BERGMANN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730143645
CMS profile
214770
Location
BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$33,400.59

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $19,559.24 24
Shire North American Group Inc $5,277.08 3
Novo Nordisk Inc $4,318.00 1
Genentech USA, Inc. $4,246.27 8

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAYLA M BERGMANN

NPI 1730143645 · CMS profile ID 214770

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1730143645?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $33,400.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $4,318.0011/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750696189 CMS
Novartis Pharmaceuticals Corporation $147.0611/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156539 CMS
Novartis Pharmaceuticals Corporation $262.1911/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156543 CMS
Novartis Pharmaceuticals Corporation $1,750.0011/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156550 CMS
Novartis Pharmaceuticals Corporation $23.8111/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156557 CMS
Novartis Pharmaceuticals Corporation $125.6311/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156563 CMS
Novartis Pharmaceuticals Corporation $15.0011/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156567 CMS
Novartis Pharmaceuticals Corporation $454.0011/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156495 CMS
Novartis Pharmaceuticals Corporation $120.1011/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156533 CMS
Novartis Pharmaceuticals Corporation $238.5611/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156501 CMS
Novartis Pharmaceuticals Corporation $391.5111/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156505 CMS
Novartis Pharmaceuticals Corporation $4,880.0011/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156511 CMS
Novartis Pharmaceuticals Corporation $120.2611/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156517 CMS
Novartis Pharmaceuticals Corporation $21.7111/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156522 CMS
Novartis Pharmaceuticals Corporation $572.0011/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156527 CMS
Novartis Pharmaceuticals Corporation $267.0007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658814037 CMS
Novartis Pharmaceuticals Corporation $280.0007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658814043 CMS
Novartis Pharmaceuticals Corporation $303.2007/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156451 CMS
Novartis Pharmaceuticals Corporation $1,438.2007/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156457 CMS
Novartis Pharmaceuticals Corporation $3,660.0007/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156461 CMS
Novartis Pharmaceuticals Corporation $17.3107/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156467 CMS
Novartis Pharmaceuticals Corporation $627.5007/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156473 CMS
Novartis Pharmaceuticals Corporation $3,660.0007/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156479 CMS
Novartis Pharmaceuticals Corporation $121.8407/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156483 CMS
Novartis Pharmaceuticals Corporation $62.3607/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659156489 CMS
Genentech USA, Inc. $48.0505/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681295443 CMS
Genentech USA, Inc. $172.8002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681199071 CMS
Genentech USA, Inc. $3,100.0002/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681174603 CMS
Genentech USA, Inc. $21.4102/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681174651 CMS
Genentech USA, Inc. $83.5202/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681195977 CMS
Genentech USA, Inc. $452.6202/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681267795 CMS
Genentech USA, Inc. $337.8702/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681289719 CMS
Genentech USA, Inc. $30.0002/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681303669 CMS
Shire North American Group Inc $84.5801/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637788741 CMS
Shire North American Group Inc $30.0001/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637788743 CMS
Shire North American Group Inc $5,162.5001/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637788739 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,400.59 36
PY2020 $17,392.19 22
PY2021 $28,307.86 31
PY2022 $56,578.29 50
PY2023 $25,272.75 24
PY2024 $93,551.59 58
PY2025 $32,786.96 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,096.67 57
PY2024 Recipient $330.00 1
PY2024 Principal investigator $123,216.25 29
PY2023 Recipient $7,690.97 4
PY2023 Principal investigator $204,898.80 60
PY2022 Recipient $2,500.00 1
PY2022 Principal investigator $196,214.82 57
PY2021 Principal investigator $297,011.90 78
PY2020 Principal investigator $507,163.73 79
PY2019 Recipient $14,782.04 33
PY2019 Principal investigator $370,237.09 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 12/16/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476390
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $8,890.00 12/03/2024 Covered Recipient Teaching Hospital
Medical University Of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1130949332
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $5,557.50 10/23/2024 Non-covered Recipient Entity
Medical University of South Carolina
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1130952280
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,414.00 10/23/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476360
Principal investigator 1 Novo Nordisk AS $1,691.82 10/17/2024 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
4202-HEM-301 No dispute reported 06/30/2026 1096885648
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $810.23 10/15/2024 Covered Recipient Teaching Hospital
Medical University Of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1130949471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 08/12/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476322
Recipient PFIZER INC. $330.00 08/01/2024 Covered Recipient Physician VOXELOTOR CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130902446
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $5,557.50 07/31/2024 Non-covered Recipient Entity
Medical University of South Carolina
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1130921178
Principal investigator 1 CSL Behring $3,913.30 07/26/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327605
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $1,359.54 07/09/2024 Covered Recipient Teaching Hospital
Medical University Of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1130949338
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,500.00 07/09/2024 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA ATTN JILL GRIFFITH
A randomized open label multicenter two arm phase II study to evaluate treatment compliance efficacy and safety of an improved deferasirox formulation granules in pediatric patients with iron overload No dispute reported 06/30/2026 1089695321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $660.00 07/01/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 1125476284
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 06/25/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476263
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $5,235.00 06/11/2024 Covered Recipient Teaching Hospital
Medical University Of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1130949477
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,850.00 06/11/2024 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA ATTN JILL GRIFFITH
A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or without Hydroxyurea Hydroxycarbamide in Sequential Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso Occlusive Crisis No dispute reported 06/30/2026 1089695225
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $8,892.00 04/17/2024 Non-covered Recipient Entity
Medical University of South Carolina
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1131057384
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $2,590.96 04/15/2024 Covered Recipient Teaching Hospital
Medical University Of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1130949958
Principal investigator 1 CSL Behring $2,000.00 04/05/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327572
Principal investigator 1 CSL Behring $2,262.00 04/05/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327574
Principal investigator 1 CSL Behring $500.00 04/05/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327576
Principal investigator 1 CSL Behring $1,000.00 04/05/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327578
Principal investigator 1 CSL Behring $1,185.60 04/05/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327580
Principal investigator 1 CSL Behring $500.00 04/05/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327621
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,434.00 03/18/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476205
Principal investigator 1 CSL Behring $14,356.80 03/11/2024 Non-covered Recipient Entity
Medical University Of South Carolina
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease No dispute reported 06/30/2026 1142327560
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,508.00 02/14/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476203
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $14,157.00 01/24/2024 Non-covered Recipient Entity
Medical University of South Carolina
AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXELOTOR No dispute reported 06/30/2026 1131077414
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,204.00 01/12/2024 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) No dispute reported 06/30/2026 1125476179
Principal investigator 1 GLOBAL BLOOD THERAPEUTICS, INC. $6,885.00 01/08/2024 Non-covered Recipient Entity
Medical University of South Carolina
AN OPENLABEL EXPANDED ACCESS PROTOCOL FOR PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WHO HAVE NO ALTERNATIVE TREATMENT OPTIONS No dispute reported 06/30/2026 1131084780